NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Sangoma Sells to BRC After Strategic Review, Deal Expected to Close Early 2027

Sangoma shareholders get $4.925 cash plus BRC stock, about $5.23 a share—a 47% premium.

Sangoma Sells to BRC After Strategic Review, Deal Expected to Close Early 2027
Credit: Sangoma Technologies
Already have an account? Sign in.
09/29/2026 · 4:58 AM
SANG
/ Read more

Feed↓

Morgan Stanley Names NetEase Its Top Pick Ahead of Ananta’s 2027 Global Launch
09/29/2026 · 5:20 AM

Morgan Stanley Names NetEase Its Top Pick Ahead of Ananta’s 2027 Global Launch

The $163 price target sits about 35% above the latest close.

/ Subscriber only
AstraZeneca Bets $2 Billion on Summit’s Dual-Target Cancer Drug
Featured/ 09/29/2026 · 4:33 AM

AstraZeneca Bets $2 Billion on Summit’s Dual-Target Cancer Drug

Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.

/ Subscriber only
U.S. Army Selects Navitas to Develop 10,000-Volt SiC Power Chips
09/28/2026 · 4:58 PM

U.S. Army Selects Navitas to Develop 10,000-Volt SiC Power Chips

The U.S. Army selected Navitas to develop 10 kV silicon carbide chips under the ALATTIS program for defense and critical infrastructure use.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe